Figure 6.
Time to detection of response to target viral antigens. (A) Time to detection of T-cell response to CMV for patients receiving VSTs as treatment (green; n = 4) and patients treated prophylactically (blue; n = 8). Time to detectable responses differed between those treated for infection vs prophylaxis (P = .019). Time to detection of T-cell response to EBV (B) for patients receiving VSTs as treatment (green; n = 2) and patients treated prophylactically (blue; n = 11). Time to detectable responses differed between those treated for infection vs prophylaxis (P = .002). Time to detection of T-cell response to Adv (C) for patients receiving VSTs as treatment (green; n = 2) and patients treated prophylactically (blue; n = 11). No difference in time to detectable response between treatment and prophylactic groups (P = .76). Time to detection of T-cell response to BKV (D) for patients receiving VSTs as treatment (green; n = 2) and patients treated prophylactically (blue; n = 3). No difference in time to detectable response between treatment and prophylactic groups (P = .617). Time to detection of T-cell response to HHV6 (E) and HPIV3 (F) for patients treated prophylactically (n = 4). Adv, adenovirus; BKV, BK virus; CMV, cytomegalovirus; HHV6, human herpes virus 6; HPIV3, human parainfluenza virus 3.

Time to detection of response to target viral antigens. (A) Time to detection of T-cell response to CMV for patients receiving VSTs as treatment (green; n = 4) and patients treated prophylactically (blue; n = 8). Time to detectable responses differed between those treated for infection vs prophylaxis (P = .019). Time to detection of T-cell response to EBV (B) for patients receiving VSTs as treatment (green; n = 2) and patients treated prophylactically (blue; n = 11). Time to detectable responses differed between those treated for infection vs prophylaxis (P = .002). Time to detection of T-cell response to Adv (C) for patients receiving VSTs as treatment (green; n = 2) and patients treated prophylactically (blue; n = 11). No difference in time to detectable response between treatment and prophylactic groups (P = .76). Time to detection of T-cell response to BKV (D) for patients receiving VSTs as treatment (green; n = 2) and patients treated prophylactically (blue; n = 3). No difference in time to detectable response between treatment and prophylactic groups (P = .617). Time to detection of T-cell response to HHV6 (E) and HPIV3 (F) for patients treated prophylactically (n = 4). Adv, adenovirus; BKV, BK virus; CMV, cytomegalovirus; HHV6, human herpes virus 6; HPIV3, human parainfluenza virus 3.

Close Modal

or Create an Account

Close Modal
Close Modal